TREPROSTINIL DRUGS MARKET ANALYSIS

Regional Analysis

Global Treprostinil Drugs Market – Regional Insights

North America accounted for the largest market share in 2018, owing to high presence of organizations involved in Treprostinil manufacturing and marketing business that have generated high revenue. For instance, in 2017, Remodulin (treprostilin injection) manufactured by the United Therapeautics, generated US$ 670.9 million, and 11.4% more than that in 2016 for the company.

Moreover, launches and approvals of various new treprostilin products are also likely to propel the market growth in the near future. For instance, in October 2019, the U.S. Food and Drug Administration (FDA) approved extended release treprostilin tablets, Orenitram, manufactured by United Therapeutics. The tablets are expected to delay to progression of pulmonary arterial hypertension disease. Similarly, in September 2019, United Therapeutics’ New Drug Application (NDA) received approved for review by the U.S. FDA for the product, Trevyent. Trevyent is a drug device combination product which contains PatchPump technology which enables treprostilin administration by subcutaneous route.